Lindy Harrell
Neurology · Birmingham, ALNPI 1164458139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 28.2% of the total. Reporting peaked in 2021 at $308 and has fallen 81.6% since, to $57 in 2025. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 61 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$304
- Indivior Inc.$95
- Novo Nordisk$87
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$78
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$65
- Novartis$56
- plus $395 from 15 others
What the payments were for
- Food & beverage$1,080100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $304 |
| Indivior Inc. | 4 | $95 |
| Novo Nordisk | 6 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Novartis | 2 | $56 |
| Boehringer Ingelheim | 3 | $44 |
| Amgen | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Lilly USA, LLC | 2 | $33 |
| Astellas Pharma US Inc | 2 | $32 |
| Pear Therapeutics (US), Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Ardelyx, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,080 in reported general payments places this provider in the 40th percentile of 255 neurology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $9,785 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $264 |
| Clonazepam | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.